The Austrian biotech company is developing endolysins and phages as therapeutics, focusing on persistent bacterial infections that cannot be targeted with broad-spectrum antibiotics. This acquisition is a big step for the AMR crisis and the formerly Phagomed team. At HEMEX, we wanted to congratulate them on their fantastic job!
Investment Press Release
hemotune makes a significant step forward: advancing into clinical trials after completing CHF 14 million Series B2 round
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Diversity Hemex Team
We welcome David to the team!
HEMEX contribution for preparing tomorrow's leaders!
Continue reading
Investment Press Release
Driving the future of non-surgical endometriosis diagnosis: Hera Biotech acquires Scailyte’s endometriosis diagnostic assets
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Hemex Team
Graphic Design Internship at HEMEX
Noémie is a student at FMS Muttenz. She completed a two-week internship at HEMEX focusing [...]
Continue reading
Hemex Team Press Release
HEMEX opens subsidiary in Belgium, expanding its presence in the EU
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
December 3rd is the international day of people with disabilities. Therefore, on this day, we’d like to raise awareness on the dignity and well-being of persons with disabilities while fostering a deeper understanding of the topic.
Continuing with HEMEX’s diversity series, we want to introduce you to our new team members Leonardo and Luana. Leonardo grew up in Milan, Italy, and Luana in the canton of Basel-Land, Switzerland. Both are dedicated to improving our society’s health system, and we are delighted with these new fresh ideas in our team! Do you want to know what brought them to HEMEX? Keep reading to find out.
HEMEX is pleased to announce the successful completion of another fundraising round. Following an oversubscribed first closing in February, our second closing of the Series C increased the round to CHF 7.1 million.
Following up on our diversity series, meet today Aurelia and Nycole. They are two outstanding young spirited women. At HEMEX, we are thrilled to have them on our team because they strengthen our work. Do you want to know a little more about their lives and how they ended up at HEMEX? Keep reading!
Today, we continue with our diversity series. In this article, please meet Andrea and Lucie. Andrea is our Clinical Research Associate from New Zealand, and Lucie is our Marketing & Sales Assistant from Czech Republic. Would you like to learn more about them?
October is known as the worldwide awareness month of breast cancer. Previously, we have talked about how early detection and personalized cancer treatment plans are key factors in breast cancer control. The purpose of this year’s message is to focus on what can be done before? We’ll talk about some preventive measures which individuals can follow to take care of their well-being.
HEMEX is pleased to introduce you to the new talented minds and charismatic personalities on the team! Are you curious? Then keep reading, because today you will learn more about our office manager and executive assistant Serena and our junior sales associate Loïc.
Diversity, Funding, Gender, Pitch Deck
2nd Diversity Series: Meet the great people and minds behind HEMEX’s success!
Unique cultures, different opportunities, and many smiles: Meet the team working towards a common goal!
We’re delighted to announce a new collaboration between HEMEX and The Bioinformatics CRO which will provide an even more complete CRO service for our start-ups! Find out how this collaboration can support you throughout your Clinical Development phase.